Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

<p>Supplementary Tables</p>

সংরক্ষণ করুন:

গ্রন্থ-পঞ্জীর বিবরন
প্রধান লেখক:	Koichi Tomoshige (15304682) (author)
অন্যান্য লেখক:	William D. Stuart (15304685) (author), Iris M. Fink-Baldauf (15304688) (author), Masaoki Ito (15304691) (author), Tomoshi Tsuchiya (15304694) (author), Takeshi Nagayasu (15304697) (author), Tomoki Yamatsuji (15304700) (author), Morihito Okada (15038418) (author), Takuya Fukazawa (15304703) (author), Minzhe Guo (15304706) (author), Yutaka Maeda (15304709) (author)
প্রকাশিত:	2025
বিষয়গুলি:	Cancer Cancer Biology Molecular and Cellular Biology Gene Regulation Promoter/enhancer analysis Lung Cancer Oncogenes & Tumor Suppressors Kras
ট্যাগগুলো:	ট্যাগ যুক্ত করুন কোনো ট্যাগ নেই, প্রথমজন হিসাবে ট্যাগ করুন!

অনুরূপ উপাদানগুলি

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S6 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S6 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S7 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S7 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure S7 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
অনুযায়ী: Craig M. Goodwin (14955973)
প্রকাশিত: (2025)

Figure 1 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
অনুযায়ী: Nicholas T. Younger (14956251)
প্রকাশিত: (2025)

Figure 2 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
অনুযায়ী: Nicholas T. Younger (14956251)
প্রকাশিত: (2025)

Figure 3 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
অনুযায়ী: Nicholas T. Younger (14956251)
প্রকাশিত: (2025)

Figure 4 from <i>In Vivo</i> Modeling of Patient Genetic Heterogeneity Identifies New Ways to Target Cholangiocarcinoma
অনুযায়ী: Nicholas T. Younger (14956251)
প্রকাশিত: (2025)

Supplementary Table 1 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
অনুযায়ী: Dhruv Chachad (14954640)
প্রকাশিত: (2025)

Supplementary Table 2 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
অনুযায়ী: Dhruv Chachad (14954640)
প্রকাশিত: (2025)

Supplementary Table 3 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
অনুযায়ী: Dhruv Chachad (14954640)
প্রকাশিত: (2025)

Supplementary Table 4 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
অনুযায়ী: Dhruv Chachad (14954640)
প্রকাশিত: (2025)

Supplementary Table 5 from Unique Transcriptional Profiles Underlie Osteosarcomagenesis Driven by Different p53 Mutants
অনুযায়ী: Dhruv Chachad (14954640)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Data from HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype
অনুযায়ী: Man Xu (14963249)
প্রকাশিত: (2025)

Supplementary Table S3 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
অনুযায়ী: Caleb N. Seavey (15056489)
প্রকাশিত: (2025)

Supplementary Table S4 from Loss of <i>CDKN2A</i> Cooperates with <i>WWTR1(TAZ)–CAMTA1</i> Gene Fusion to Promote Tumor Progression in Epithelioid Hemangioendothelioma
অনুযায়ী: Caleb N. Seavey (15056489)
প্রকাশিত: (2025)

Cannot write session to /tmp/vufind_sessions/sess_ct788f98kk519a00adeqdmoqec